Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ex scientia Ltd
ex scientia Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Transatlantic partnership to screen 15,000 drugs for COVID-19 treatments
Exscientia has announced a joint initiative to identify COVID-19 drugs with Diamond Light Source and Scripps Research
Research & Development
Exscientia initiates sixth AI drug discovery partnership
Exscientia to receive up to CHF67 million in upfront payments, research support and milestone payments in discovery collaboration with Roche
Analysis
Exscientia appoints Georgy Egorov as Chief Financial Officer
Research & Development
Elsevier welcomes six biotech and pharma start-ups to The Hive
Start-ups working on a range of technologies and discoveries — from AI to immunotherapy — receive complimentary access to Elsevier's information solutions to accelerate innovation
Recruitment
Exscientia appoints Alex Snow as Deputy Chairman
Digital
Exscientia enters drug discovery collaboration with GSK
Exscientia, an innovative artificial intelligence driven drug discovery company, has entered into a strategic drug discovery collaboration with GlaxoSmithKline
Research & Development
Collaboration in bispecific-small-molecule drugs for metabolic disease
€250m agreement between Exscientia and Sanofi is for multiple-product development and licence option
Subscribe now